Biological Mimetics, Inc.
Privately held biomedical company (founded 1996) focused on vaccine design and point-of-care diagnostics. Core activities include computational epitope prediction and immune-refocusing for antigen design, development of UVC-based pathogen inactivation for inactivated vaccines, and low-resource microfluidic CRISPR/RPA diagnostic devices. The organization conducts preclinical development, collaborates with academic and government partners, and pursues grant-funded research.
Industries
N/A
Nr. of Employees
small (1-50)
Biological Mimetics, Inc.
Patents
Irradiation-inactivated poliovirus, compositions including the same, and methods of preparation
US-12042533-B2
View Details
Irradiation-inactivated poliovirus, compositions including the same, and methods of preparation
US-12042533-B2
View DetailsProducts
Power-free funnel-adapted sensing tube for nucleic acid detection
Disposable multi-chambered microfluidic device enabling pipette-free sample processing and sequential reactions (disruption, RPA, CRISPR cleavage) with visual or camera-based readout.
UVC inactivation vaccine platform with manganese-peptide complex
Inactivated vaccine platform that complexes pathogens with a manganese-peptide-phosphate formulation prior to UVC irradiation to produce inactivated vaccine candidates intended for IND-enabling development.
Ellipsometry-based rapid bacterial identification platform
Optical, label-free biosensing approach under development to rapidly identify bacterial infections for clinical decision support in emergency and rapid clinic settings.
Power-free funnel-adapted sensing tube for nucleic acid detection
Disposable multi-chambered microfluidic device enabling pipette-free sample processing and sequential reactions (disruption, RPA, CRISPR cleavage) with visual or camera-based readout.
UVC inactivation vaccine platform with manganese-peptide complex
Inactivated vaccine platform that complexes pathogens with a manganese-peptide-phosphate formulation prior to UVC irradiation to produce inactivated vaccine candidates intended for IND-enabling development.
Ellipsometry-based rapid bacterial identification platform
Optical, label-free biosensing approach under development to rapidly identify bacterial infections for clinical decision support in emergency and rapid clinic settings.
Services
Research collaborations, sponsored projects, and partnerships to advance vaccines and diagnostics from prototype to deployment.
Design, prototyping, and beta-testing support for power-free, instrument-free nucleic acid diagnostic devices and reagents.
Production of GLP/GMP-like lots for animal safety and efficacy studies and preparation of regulatory documentation for IND submissions.
Research collaborations, sponsored projects, and partnerships to advance vaccines and diagnostics from prototype to deployment.
Design, prototyping, and beta-testing support for power-free, instrument-free nucleic acid diagnostic devices and reagents.
Production of GLP/GMP-like lots for animal safety and efficacy studies and preparation of regulatory documentation for IND submissions.
Expertise Areas
- Vaccine design and preclinical development
- Point-of-care nucleic acid diagnostics
- Immunoinformatics and epitope engineering
- CRISPR-based molecular detection
Key Technologies
- CRISPR-based diagnostics (Cas12a/Cas13-type detection)
- Recombinase polymerase amplification (RPA)
- Microfluidic multi-chamber devices
- PVA sacrificial-core chip fabrication
News & Updates
Peer-reviewed article describing the FAST microfluidic device: four-chamber chip, RPA + CRISPR reaction, PVA fabrication, power-free operation, and a computer vision linear-kernel algorithm for optical readout.
Peer-reviewed article describing the FAST microfluidic device: four-chamber chip, RPA + CRISPR reaction, PVA fabrication, power-free operation, and a computer vision linear-kernel algorithm for optical readout.